Efficacy of Thymosin alpha1 for Severe Sepsis
NCT00711620 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 366
Last updated 2011-06-14
Summary
The purpose of this study is to evaluate the efficacy of thymosin alpha 1 for treating severe sepsis.
Conditions
- Severe Sepsis
Interventions
- DRUG
-
Thymosin alpha 1
1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.
Sponsors & Collaborators
-
Sun Yat-sen University
lead OTHER
Principal Investigators
-
Guan Xiangdong, M.D · Sun Yat-sen University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-05-31
- Primary Completion
- 2010-12-31
- Completion
- 2011-01-31
Countries
- China
Study Locations
More Related Trials
-
Immunoregulatory Therapy for 2019-nCoV
NCT04268537 ·Status: UNKNOWN ·Phase: PHASE2
-
Study on the Role of Gamma Delta T Cells in Sepsis Immunosuppression and Its Molecular Mechanism
NCT02361970 ·Status: COMPLETED
-
Evidence-based Evaluation and Mechanism of Shenhuang Granules in the Treatment of Sepsis
NCT06514339 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
The Efficacy of Si-Ni-Tang (a Chinese Herbal Formula) for Severe Sepsis
NCT02777606 ·Status: COMPLETED ·Phase: NA
-
Dynamic Changes of Tim-3 on Monocytes and Soluble Tim-3 in Patients With Sepsis
NCT02180009 ·Status: COMPLETED
-
Identification and Clinical Efficacy Analysis of Biomarkers in Sepsis Patients
NCT05911711 ·Status: UNKNOWN
-
Myeloid-derived Suppressor Cells in Sepsis
NCT03540797 ·Status: UNKNOWN
-
The Effect of Moderate-Dose Steroid Therapy in Sepsis
NCT01275638 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis
NCT05634057 ·Status: RECRUITING ·Phase: NA
-
Continuos Terlipressin Infusion in Septic Shock
NCT01697410 ·Status: UNKNOWN ·Phase: NA
-
Improvement of Organ Function by Apigenin in Elderly Patients With Sepsis
NCT05999682 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Efficacy of YiQiFuMai Injection as an Adjunctive Treatment for Sepsis
NCT05265130 ·Status: UNKNOWN ·Phase: PHASE4
-
Unfractioned Heparin for Treatment of Sepsis Caused by Abdominal Infection
NCT04861922 ·Status: UNKNOWN ·Phase: PHASE3
-
Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes
NCT06390748 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients
NCT04803955 ·Status: RECRUITING ·Phase: PHASE2
-
Causes and Factors Associated With Outcomes in Community-acquired Sepsis and Severe Sepsis in Northeast Thailand
NCT02217592 ·Status: COMPLETED
-
Phase 3 Safety and Efficacy Study of ART-123 in Subjects With Severe Sepsis and Coagulopathy
NCT01598831 ·Status: COMPLETED ·Phase: PHASE3
-
Pro-inflammatory Cytokines Profile and Mortality Rate of Critically Ill Septic Patients Following Plasmapheresis
NCT01249222 ·Status: UNKNOWN ·Phase: NA
-
Alpha-lipoic Acid in Critically Ill Patients With Sepsis
NCT06661993 ·Status: COMPLETED ·Phase: NA
-
Investigate the Activity of Endotoxin in Severe Sepsis
NCT01957254 ·Status: TERMINATED
-
Study of Multiple-dose Kukoamine B Mesilate in Sepsis Patients
NCT03237728 ·Status: COMPLETED ·Phase: PHASE1
-
Urine Interleukin-37 as a Biomarker of Mortality Risk in Patients With Sepsis
NCT05640037 ·Status: COMPLETED
-
Host Dysregulation-Driven Sepsis Prediction Model
NCT06523075 ·Status: COMPLETED
-
The Predictive Value of Hepatocyte Growth Factor and Soluble Receptor s-Met in Sepsis
NCT03340649 ·Status: UNKNOWN
-
Protective Effect of Sivelestat Sodium on ARDS in Patients With Sepsis
NCT04973670 ·Status: UNKNOWN ·Phase: PHASE3